Table.
Baseline characteristics, effect sizes, and quality scores of included trials
| Study | Intervention* | No who completed trial | Drop out rate (%) | Boys (%) | Mean age (weeks) (range) | Age at onset of colic (weeks) | Breast fed (%)† | Firstborn (%) | Baseline crying (h/day) | Effect size (%) (95% CI) | Quality score (range 0-5) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Evans et al14 | Soy formula milk | 20 | NR | 40 | 7 (3-18) | 3 | 100 | 0.05 (−0.01 to 0.11) | 3 | ||
| Lothe et al15 | Soy formula milk | 60 | 8 | 38 | (2-13) | 8 | 0.18 (0.08 to 0.28) | 1 | |||
| Campbell16 | Soy formula milk | 19 | NR | 58 | 7 (3-14) | 2 | 0 | 21 | 0.63 (0.29 to 0.97) | 3 | |
| Forsyth17 | Hypoallergenic formula milk | 17 | 47 | 65 | 5 (<8) | 0 | 3-4 | 0.25 (0.07 to 0.44) | 5 | ||
| Hill et al18 | Hypoallergenic formula milk | 115 | 24 | 7 (4-16)‡ | 2 | 67 | 51 | 0.18 (0.01 to 0.36) | 3 | ||
| Ståhlberg and Savilahti19 | Low lactase | 10 | NR | 12 | 4 | 0 | 0.20 (−0.37 to 0.77) | 3 | |||
| Miller et al20 | Low lactase | 12 | 20 | 42 | 7-8 (3-9)‡ | 0 | 0.11 (−0.59 to 0.80) | 3 | |||
| Jain and Tripathi21 | Herbal mixture | 100 | NR | 0.76 (0.62 to 0.89) | 0 | ||||||
| Treem et al22 | Fibre | 27 | 18 | 48 | 5 (1-8) | 2 | 0 | 56 | 5-6 | 0.26 (−0.11 to 0.63) | 3 |
| Weizman et al23 | Herbal tea | 68 | 6 | 38 | 3 (2-8)‡ | 69 | 63 | 3-4§ | 0.32 (0.10 to 0.54) | 5 | |
| Illingworth24 | Dicyclomine | 16 | 20 | 0.38 (−0.02 to 0.77) | 1 | ||||||
| Grunseit25 | Dicycloverine | 22 | 12 | 41 | 5 (3-12) | 73 | 0.59 (0.28 to 0.90) | 4 | |||
| Blomquist et al26 | Dicyclomine | 18 | NR | 44 | (2-14) | 89 | 33 | 0.56 (0.23 to 0.88) | 3 | ||
| Weissbluth et al27 | Dicyclomine | 48 | 13 | 58 | 5 | 2 | 50 | 50 | 0.38 (0.12 to 0.63) | 2 | |
| Hwang and Danielsson28 | Dicyclomine | 30 | NR | 4.5 | 4.9 | 0.43 (0.13 to 0.74) | 2 | ||||
| Danielsson and Hwang29 | Simethicone | 27 | 16 | 44 | 5 (2-8) | 96 | 6.3 | 0.06 (−0.17 to 0.28) | 3 | ||
| Sehti and Sehti30 | Simethicone | 26 | 10 | 38 | (1-12) | 0.54 (0.21 to 0.87) | 1 | ||||
| Metcalf et al31 | Simethicone | 83 | NR | 49 | (2-8)‡ | 49 | −0.10 (−0.27 to 0.08) | 5 | |||
| Illingworth32 | Other drug treatment | 40 | NR | 55 | 5 | 80 | 63 | −0.10 (−0.37 to 0.17) | 1 | ||
| O’Donovan and Bradstock33 | Other drug treatment | 97 | 12 | 49 | (2-6)‡ | 7 | −0.15 (−0.39 to 0.09) | 1 | |||
| Barr et al34 | Behavioural | 66 | 7 | 36 | 3 | 68 | 77 | 3.4 (SD 1.7) | 0.12 (−0.03 to 0.27) | 3 | |
| McKenzie35 | Behavioural | 42 | 7 | 10¶ | 0.48 (0.23 to 0.74) | 3 | |||||
| Parkin et al36 | Behavioural | 38 | 16 | 68 | 7 | 55 | 66 | 5.7 (SD 2.4) | −0.37 (−0.69 to −0.05) | 3 | |
| Wolke et al37 | Behavioural | 92 | 0 | 50 | 13 (<26)‡ | 39 | 59 | 5.8 | 0.16 (0.02 to 0.30) | 1 | |
| Westphal and Medin38 | Simethicone, methylscopolamine | 24 | 8 | 6-7 | 54 | 0.33 (0.11 to 0.56) | 1 | ||||
| Taubman39 | Behavioural, hypoallergenic formula milk | 20 | 5 | 6 (<12)‡ | 35 | 30 | 3.2 | 0.30 (0.06 to 0.55) | 3 | ||
| Oggero et al40 | Dicyclomine, diet soy or hypoallergenic formula milk | 120 | NR | 7 (3-12) | 26 | >3 | −0.42 (−0.58 to −0.26) | 1 |
NR=not reported.
*
All trials used placebo or standard treatment except references 38-40.
†
Total or partial breast feeding.
‡
Age not given in results, but stated in inclusion criteria.
§
Data obtained from published letter from authors.41
¶
Median.